Oncologia hepàtica (BCLC)
Publicacions destacades
-
BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system
Reig M; Forner A; Rimola J; Ferrer-Fábrega J; Burrel M;(...)Singal AG; Vogel A; Fuster J; Ayuso C; Bruix J .Referència:Journal Of Hepatology 2022.
-
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis
Sapena V; Enea M; Torres F; Celsa C; Rios J;(...)Trevisani F; Cammà C; Bruix J; Cabibbo G; Reig M .Referència:Gut 2022.
-
Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules
Sanduzzi-Zamparelli M; Mariño Z; Lens S; Sapena V; Iserte G;(...)Forner A; Torres F; Bruix J; Forns X; Reig M .Referència:Journal Of Hepatology 2022.
-
Antiviral therapy in the palliative setting of HCC (BCLC B and C)
Reig M; Cabibbo G ;Referència:Journal Of Hepatology 2021.
-
Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma
Corominas J; Sapena V; Sanduzzi-Zamparelli M; Millán C; Samper E;(...)Muñoz-Martínez S; Forner A; Bruix J; Boix L; Reig M .Referència:Cancers 2021.
-
Regorafenib efficacy after sorafenib in patients with recurrent HCC after liver transplantation: a retrospective study
Iavarone M; Invernizzi F; Ivanics T; Mazza S; Zavaglia C;(...)Wörns MA; Bruix J; Sapisochin G; Lampertico P; Reig M .Referència:Liver Transplantation 2021.
-
Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation
Iavarone M; Invernizzi F; Czauderna C; Sanduzzi-Zamparelli M; Bhoori S;(...)Varela M; Wörns MA; Bruix J; Lampertico P; Reig M .Referència:American Journal Of Transplantation 2019.
-
Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules
Mariño Z; Darnell A; Lens S; Sapena V; Díaz A;(...)Ayuso C; Ríos J; Forns X; Bruix J; Reig M .Referència:Journal Of Hepatology 2019.
-
New trials and results in systemic treatment of HCC.
Reig M; da Fonseca LG; Faivre S ;Referència:Journal Of Hepatology 2018.
-
Complete response under sorafenib in patients with hepatocellular carcinoma. Relationship with dermatologic adverse events.
Rimola J; Díaz-González Á; Darnell A; Varela M; Pons F;(...)Huertas C; Minguez B; Ayuso C; Bruix J; Reig M .Referència:Hepatology 2018.